Is CAJPY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Imaging and network cameras, with revenue (ttm) at ~¥4.7 trillion (2026 guidance ~¥4.8 trillion). The bear case rests on printing is in long-term structural decline as offices print less, so Canon must keep finding growth elsewhere to offset a segment that still produces over half its sales. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Printing is in long-term structural decline as offices print less, so Canon must keep finding growth elsewhere to offset a segment that still produces over half its sales. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

Imaging and network cameras. Imaging was the standout segment in 2026, with second-quarter sales up ~17.7% as demand for compact cameras surged among younger buyers and the Axis-led network camera business kept growing on security and video analytics demand.

Printing is in long-term structural decline as offices print less, so Canon must keep finding growth elsewhere to offset a segment that still produces over half its sales. The medical segment has suffered production disruptions and component shortages in 2026 and has historically earned thin margins (~5.6% in 2025) relative to the price Canon paid for Toshiba Medical. Higher memory chip prices, energy and materials costs linked to the Middle East situation and shifting US trade policy all pressure margins; Canon's 2026 plan includes ~¥35 billion of expected Middle East headwinds and ~¥6 billion from memory costs, offset by ~¥37.5 billion of tariff relief that may not recur. Competition is intense in every segment, from Sony in cameras to ASML and Nikon in lithography and Siemens Healthineers and GE HealthCare in medical. For CAJPY holders specifically, returns are earned in yen and converted to dollars, so a stronger yen can raise the ADR price while hurting Canon's reported profit, and vice versa; dividends are paid in yen, converted by the depositary (minus fees) and may be subject to Japanese withholding tax. The ADR trades over the counter rather than on an exchange, which can mean wider bid-ask spreads and less liquidity than the Tokyo shares.

Tokyo-based maker of office printers, cameras, medical imaging systems and semiconductor lithography equipment.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Imaging and network cameras) stalling in the reported numbers rather than in the narrative, the risk above (printing is in long-term structural decline as offices print less, so Canon must keep finding growth elsewhere to offset a segment that still produces over half its sales) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

CAJPY is the ticker for Canon Inc.'s American Depositary Receipt, a certificate that lets US investors own Canon shares in dollars through a US brokerage account. Canon's primary listing is on the Tokyo Stock Exchange under code 7751. The ADR used to trade on the New York Stock Exchange as CAJ, but Canon voluntarily delisted from the NYSE in 2016, and the ADR has traded over the counter as CAJPY since then. Each CAJPY ADR represents one ordinary Canon share, so its dollar price tracks the Tokyo price converted at the current yen exchange rate. Because Tokyo and New York trading hours do not overlap, the ADR often reacts in the US morning to moves that already happened in Tokyo overnight.

Canon has four segments. Printing, which includes office multifunction printers, laser and inkjet printers and commercial production presses, is the largest at ~¥2.49 trillion of 2025 sales, and much of its profit comes from toner, ink and service rather than the machines themselves. Imaging covers mirrorless and compact cameras, lenses and network surveillance cameras through its Axis subsidiary, and produced ~¥1.05 trillion of sales at a ~16% margin. Medical sells CT, MRI, ultrasound and X-ray systems through Canon Medical Systems (~¥581 billion). Industrial makes semiconductor lithography equipment and display manufacturing tools. Most of Canon's sales come from outside Japan, mainly the Americas, Europe and Asia, which is why currency moves have such a large effect on its reported results.

Canon reported a record second quarter in July 2026, with sales of ~¥1.18 trillion (+3.6%) and operating profit up ~35% to ~¥159 billion, helped by strong compact and network camera demand and refunds of additional US tariffs. First-half sales rose ~3.5% to ~¥2.27 trillion. Medical sales fell on production disruptions and component shortages, and industrial sales dropped ~15% as display equipment demand weakened. Canon raised its full-year operating profit forecast to ~¥465 billion, on sales of ~¥4.8 trillion and net income of ~¥340 billion, while flagging higher memory and energy costs as headwinds. For context, full-year 2025 operating profit was ~¥455 billion on ~¥4.62 trillion of sales, so the 2026 plan implies only modest growth.